Aarti Pharmalabs' Q4 FY 2025-26 Quarterly Results

Result Summary

• Aarti Pharmalabs Ltd reported a 36.8% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 5.1%.
• Its expenses for the quarter were up by 38.6% QoQ and 15.0% YoY.
• The net profit increased 27.4% QoQ and decreased 30.8% YoY.
• The earnings per share (EPS) of Aarti Pharmalabs Ltd stood at 6.74 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Aarti Pharmalabs Ltd is a pharmaceutical company engaged in the production and distribution of active pharmaceutical ingredients (APIs) and other chemical compounds. The company operates within the pharmaceutical industry, which involves the development, production, and marketing of medications. As of the latest known information, Aarti Pharmalabs focuses on catering to both domestic and international markets, leveraging its expertise in chemical manufacturing. However, specific recent developments or strategic moves by the company are not available in the provided data.

Revenue

In the fourth quarter of fiscal year 2026 (Q4FY26), Aarti Pharmalabs Ltd reported a total income of ₹590.70 crores. This marks a significant quarter-over-quarter (QoQ) increase of 36.8% from ₹431.90 crores in the third quarter of fiscal year 2026 (Q3FY26). Year-over-year (YoY), the total income grew by 5.1% from ₹562.17 crores in the fourth quarter of fiscal year 2025 (Q4FY25). These figures demonstrate a notable growth in revenue during the latest quarter compared to both the previous quarter and the same quarter in the prior year.

Profitability

The profit before tax for Aarti Pharmalabs Ltd in Q4FY26 stood at ₹76.17 crores, reflecting a 31.5% QoQ increase from ₹57.94 crores in Q3FY26. On a YoY basis, however, there was a decline of 33.5% from ₹114.62 crores in Q4FY25. The tax expense for Q4FY26 was ₹20.55 crores, which increased by 37.8% QoQ compared to ₹14.91 crores in Q3FY26 and decreased by 21.8% YoY from ₹26.28 crores in Q4FY25. Consequently, the profit after tax was ₹61.12 crores in Q4FY26, increasing by 27.4% QoQ from ₹47.96 crores in Q3FY26, yet decreasing by 30.8% YoY from ₹88.34 crores in Q4FY25. Earnings per share (EPS) aligned with these trends, recorded at ₹6.74 in Q4FY26, up by 27.4% QoQ but down by 30.8% YoY.

Operating Metrics

Total expenses for Aarti Pharmalabs Ltd in Q4FY26 were ₹514.53 crores, showing a 38.6% QoQ increase from ₹371.16 crores in Q3FY26. YoY, the expenses rose by 15.0% from ₹447.55 crores in Q4FY25. This increase in expenses, both QoQ and YoY, corresponds with the changes in total income and profitability metrics. The company's operating performance is reflected in these financial metrics, indicating the cost management and efficiency in resource utilization during the reported periods.